Zobrazeno 1 - 10
of 43
pro vyhledávání: '"D. A. Kudlai"'
Autor:
Yu. G. Samoilova, M. V. Matveeva, D. V. Podchinenova, O. A. Oleynik, L. M. Shuliko, M. A. Kovarenko, D. A. Kudlai
Publikováno v:
Ожирение и метаболизм, Vol 21, Iss 2, Pp 116-124 (2024)
BACKGROUND: Obesity is a progressive health and economic problem of modern society. Endocrine-metabolic changes in childhood and adolescence have an impact on cognitive status, which is accompanied by changes in the perfusion of gray and white matter
Externí odkaz:
https://doaj.org/article/ef5183a8acfe4a0e9ca00ee064538058
Autor:
O. L. Ekaterincheva, A. M. Malkova, V. E. Karev, I. V. Kudryavtsev, Yu. S. Zinchenko, T. B. Potepun, D. A. Kudlai, A. A. Starshinova
Publikováno v:
Журнал инфектологии, Vol 13, Iss 1, Pp 117-123 (2021)
2020 began with the most significant pandemic COVID-19 in the history of this century. The epidemiology indicators are growing every day. The spread of COVID-19 may affect an increase in the incidence of tuberculosis, despite a decrease in the incide
Externí odkaz:
https://doaj.org/article/abda797800914d8a9e97afc4647dbf46
Autor:
D. A. Kudlai, Igor Kudryavtsev, O. L. Ekaterincheva, Yu S. Zinchenko, T. B. Potepun, A. M. Malkova, Anna Starshinova, V. E. Karev
Publikováno v:
Žurnal Infektologii, Vol 13, Iss 1, Pp 117-123 (2021)
2020 began with the most significant pandemic COVID-19 in the history of this century. The epidemiology indicators are growing every day. The spread of COVID-19 may affect an increase in the incidence of tuberculosis, despite a decrease in the incide
Autor:
O. B. Ustinnikova, D. V. Shvedov, E. V. Novikova, D. A. Kudlai, M. V. Zhilyaeva, O. B. Runova
Publikováno v:
Pharmaceutical Chemistry Journal. 51:500-503
The interchangeability of coagulation methods for determining the activity of recombinant blood clotting factor rFVIIa was assessed. Single-factor analysis of variance (ANOVA) and comparison of the metrological characteristics of the methods led to t
Publikováno v:
Eksperimental'naia i klinicheskaia farmakologiia. 78(12)
Rituximab is a chimeric monoclonal antibody containing constant kappa-regions of the Fc fragment of IgGI human immunoglobulin and variable fragments of IgG murine immunoglobulin. This modified immunoglobulin structure makes rituximab capable of speci
Autor:
V G, PETROVSKAIA, D G, KUDLAI
Publikováno v:
Antibiotiki. 3(5)
Publikováno v:
Bulletin of Experimental Biology and Medicine. 75:76-78
Autor:
D G, Kudlai, M A, Gurgenidze
Publikováno v:
Soviet genetics. 8(3)
Publikováno v:
Soviet genetics. 9(1)
Autor:
D G, KUDLAI
Publikováno v:
Zhurnal mikrobiologii, epidemiologii i immunobiologii. 33